iBio Inc (NYSE: IBIO) has provided an update on its IBIO-201 program and reported its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection.
IBIO-201 combines antigens derived from the spike protein ("S protein") fused with iBio's patented LicKM booster molecule
It recently completed IND-enabling toxicology studies. No adverse effects at low or high doses were identified.
The Company also reported on the development of IBIO-202, a subunit vaccine candidate that targets the nucleocapsid protein ("N protein") of SARS-CoV-2.
"In light of the successful global roll-out of COVID-19 vaccines targeting the S protein and the emergence of variant strains of the disease, we decided to focus our efforts on the continued development of IBIO-202 as a differentiated vaccine candidate," said Tom Isett, Chairman, and CEO.
iBio has expressed N protein antigens and initiated intramuscular and intranasal preclinical studies to identify favorable antigen-adjuvant combinations using its plant-based FastPharming System.
Results are expected in early Q1 FY2022.
Price Action: IBIO shares are 30.4% at $1.80 during premarket trading on the last check Friday.
See more from Benzinga
Click here for options trades from Benzinga
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
Symbol Last Price Change % Change IBIOiBio, Inc. 1.6100 +0.2300 +16.67% Symbol Last Price Change % Change ACCRAccess-Power & Co., Inc. 0.0240 +0.0066 +37.93% AABBAsia Broadband, Inc. 0.1869 +0.0360 +23.81% FTOCFTAC Olympus Acquisition Corp. 10.08 0.00 0.00% GOEVWCanoo Holdings Ltd. 1.9100 +0.1200 +6.70% AGCUUAltimeter Growth Corp. 12.35 -0.05 -0.40% TRENDING 1. Citi Defeat on $500 Million Error Was Wrong, Groups Say 2. UPDATE 1-AstraZeneca weighs seeking full U.S. approval for COVID shot - WSJ 3. Hertz Says Travel Demand Returning After 33% Revenue Decline 4. UPDATE 1-CDC says U.S.-bound air travelers can use some self-administered COVID-19 tests 5. Khan Academy’s Sal Khan on the future of higher education and why it might include non-traditional methods